Deborah M. Messemer Sells 9,136 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) Director Deborah M. Messemer sold 9,136 shares of Allogene Therapeutics stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $2.18, for a total value of $19,916.48. Following the transaction, the director now directly owns 157,629 shares of the company's stock, valued at $343,631.22. The trade was a 5.48 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Allogene Therapeutics Trading Down 3.5 %

Shares of NASDAQ ALLO opened at $2.19 on Wednesday. The firm has a market capitalization of $459.18 million, a price-to-earnings ratio of -1.40 and a beta of 0.83. The business has a 50-day moving average of $2.58 and a 200-day moving average of $2.59. Allogene Therapeutics, Inc. has a 12 month low of $1.99 and a 12 month high of $5.78.

Institutional Trading of Allogene Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA boosted its stake in Allogene Therapeutics by 4.1% in the second quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company's stock worth $13,212,000 after buying an additional 221,840 shares in the last quarter. Geode Capital Management LLC boosted its stake in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company's stock worth $9,037,000 after buying an additional 407,070 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Allogene Therapeutics in the second quarter worth approximately $6,349,000. Dimensional Fund Advisors LP boosted its stake in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company's stock worth $5,944,000 after buying an additional 507,021 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in Allogene Therapeutics in the second quarter worth approximately $5,192,000. Hedge funds and other institutional investors own 83.63% of the company's stock.

Wall Street Analyst Weigh In


Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.


ALLO has been the subject of a number of recent analyst reports. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler reduced their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $9.73.

Get Our Latest Research Report on ALLO

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

See Also

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Allogene Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Allogene Therapeutics and related companies.
More From MarketBeat
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles